| Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (NCT02753686) | Novartis Pharmaceuticals | 2016-03-15 |
| Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China (NCT02842749) | Novartis Pharmaceuticals | 2016-03-14 |
| Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting (NCT02690974) | Novartis Pharmaceuticals | 2016-03-08 |
| Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects (NCT02758548) | Novartis Pharmaceuticals | 2016-03-01 |
| CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab (NCT02634970) | Novartis Pharmaceuticals | 2016-03-01 |
| Phase I Study of PDR001 in Patients With Advanced Malignancies. (NCT02678260) | Novartis Pharmaceuticals | 2016-02-19 |
| Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NCT02546674) | Novartis Pharmaceuticals | 2016-02-18 |
| Effect of Fingolimod on Neurodegeneration (NCT02575365) | Novartis Pharmaceuticals | 2016-02-16 |
| Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event (NCT02661217) | Novartis Pharmaceuticals | 2016-02-12 |
| Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (NCT02690701) | Novartis Pharmaceuticals | 2016-02-10 |
| Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure (NCT02625922) | Novartis Pharmaceuticals | 2016-02-05 |
| Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (NCT02598297) | Novartis Pharmaceuticals | 2016-02-03 |
| A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. (NCT02601378) | Novartis Pharmaceuticals | 2016-02-01 |
| Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (NCT02607813) | Novartis Pharmaceuticals | 2016-01-18 |
| SCHEDULE Follow Up Visit 5-7 yr (NCT02864706) | Novartis Pharmaceuticals | 2016-01-18 |
| To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea. (NCT02713243) | Novartis Pharmaceuticals | 2016-01-16 |
| Head to Head Study of Anti-VEGF Treatment. (NCT02577107) | Novartis Pharmaceuticals | 2016-01-13 |
| RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (NCT02375971) | Novartis Pharmaceuticals | 2015-12-30 |
| A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma (NCT02554786) | Novartis Pharmaceuticals | 2015-12-29 |
| A Registry of Patients With Moderate to Severe Plaque Psoriasis (NCT02786186) | Novartis Pharmaceuticals | 2015-12-23 |
| Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment. (NCT02624557) | Novartis Pharmaceuticals | 2015-12-21 |
| Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis (NCT02607774) | Novartis Pharmaceuticals | 2015-12-17 |
| Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib (NCT02115386) | Novartis Pharmaceuticals | 2015-12-17 |
| Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices (NCT02596009) | Novartis Pharmaceuticals | 2015-12-16 |
| Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study (NCT02584933) | Novartis Pharmaceuticals | 2015-12-11 |
| Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. (NCT02555683) | Novartis Pharmaceuticals | 2015-12-11 |
| A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors (NCT02520752) | Novartis Pharmaceuticals | 2015-12-10 |
| Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma (NCT02571777) | Novartis Pharmaceuticals | 2015-12-08 |
| A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors (NCT02626234) | Novartis Pharmaceuticals | 2015-12-08 |
| Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. (NCT02563067) | Novartis Pharmaceuticals | 2015-12-03 |
| Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome (NCT02495129) | Novartis Pharmaceuticals | 2015-12-01 |
| A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (NCT02565511) | Novartis Pharmaceuticals | 2015-11-30 |
| Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (NCT02608268) | Novartis Pharmaceuticals | 2015-11-23 |
| Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD (NCT02603393) | Novartis Pharmaceuticals | 2015-11-20 |
| Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL (NCT02603445) | Novartis Pharmaceuticals | 2015-11-16 |
| First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (NCT02491281) | Novartis Pharmaceuticals | 2015-11-16 |
| A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function (NCT02399202) | Novartis Pharmaceuticals | 2015-11-06 |
| Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients (NCT02515331) | Novartis Pharmaceuticals | 2015-11-04 |
| An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 (NCT02573467) | Novartis Pharmaceuticals | 2015-11-02 |
| CAR-T Long Term Follow Up (LTFU) Study (NCT02445222) | Novartis Pharmaceuticals | 2015-11-02 |
| Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer (NCT01613677) | Novartis Pharmaceuticals | 2015-11-01 |
| Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes (NCT01824264) | Novartis Pharmaceuticals | 2015-11-01 |
| Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011 (NCT02431481) | Novartis Pharmaceuticals | 2015-10-23 |
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors (NCT02422589) | Novartis Pharmaceuticals | 2015-10-23 |
| Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload (NCT02435212) | Novartis Pharmaceuticals | 2015-10-21 |
| Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort (NCT02516592) | Novartis Pharmaceuticals | 2015-10-13 |
| Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (NCT02258009) | Novartis Pharmaceuticals | 2015-10-01 |
| Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis (NCT02565576) | Novartis Pharmaceuticals | 2015-09-29 |
| Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis (NCT02471144) | Novartis Pharmaceuticals | 2015-09-29 |
| Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome (NCT02468193) | Novartis Pharmaceuticals | 2015-09-24 |
| A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification (NCT02468661) | Novartis Pharmaceuticals | 2015-09-23 |
| A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients (NCT02570854) | Novartis Pharmaceuticals | 2015-09-22 |
| Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload (NCT05440487) | Novartis Pharmaceuticals | 2015-09-15 |
| A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients (NCT02516605) | Novartis Pharmaceuticals | 2015-09-09 |
| Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT02534909) | Novartis Pharmaceuticals | 2015-09-09 |
| Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT02551224) | Novartis Pharmaceuticals | 2015-09-01 |
| Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients. (NCT03596970) | Novartis Pharmaceuticals | 2015-09-01 |
| Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma (NCT02336425) | Novartis Pharmaceuticals | 2015-09-01 |
| Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (NCT02404350) | Novartis Pharmaceuticals | 2015-08-31 |
| Study of Efficacy of CDZ173 in Patients With APDS/PASLI (NCT02435173) | Novartis Pharmaceuticals | 2015-08-24 |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (NCT02450903) | Novartis Pharmaceuticals | 2015-08-21 |
| A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera (NCT05853445) | Novartis Pharmaceuticals | 2015-08-17 |
| Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age (NCT02576639) | Novartis Pharmaceuticals | 2015-08-10 |
| Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (NCT02435680) | Novartis Pharmaceuticals | 2015-08-10 |
| The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA (NCT02333344) | Novartis Pharmaceuticals | 2015-07-30 |
| Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (NCT02445248) | Novartis Pharmaceuticals | 2015-07-29 |
| Efficacy and Safety Study of QVA149 in COPD Patients (NCT02487446) | Novartis Pharmaceuticals | 2015-07-28 |
| Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. (NCT02487498) | Novartis Pharmaceuticals | 2015-07-27 |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (NCT02437318) | Novartis Pharmaceuticals | 2015-07-23 |
| A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study (NCT02468674) | Novartis Pharmaceuticals | 2015-07-22 |
| Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months. (NCT02670928) | Novartis Pharmaceuticals | 2015-07-20 |
| Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU (NCT02477332) | Novartis Pharmaceuticals | 2015-07-15 |
| Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos (NCT02543086) | Novartis Pharmaceuticals | 2015-07-01 |
| A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD (NCT02371629) | Novartis Pharmaceuticals | 2015-06-24 |
| Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (NCT02460224) | Novartis Pharmaceuticals | 2015-06-17 |
| Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A (NCT02547714) | Novartis Pharmaceuticals | 2015-06-16 |
| Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction (NCT02468232) | Novartis Pharmaceuticals | 2015-06-15 |
| INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function (NCT02474537) | Novartis Pharmaceuticals | 2015-06-12 |
| Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) (NCT02414139) | Novartis Pharmaceuticals | 2015-06-11 |
| Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (NCT02422615) | Novartis Pharmaceuticals | 2015-06-09 |
| Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index (NCT02470403) | Novartis Pharmaceuticals | 2015-06-05 |
| Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients (NCT02268526) | Novartis Pharmaceuticals | 2015-06-02 |
| Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications (NCT04847895) | Novartis Pharmaceuticals | 2015-06-01 |
| 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis (NCT02294227) | Novartis Pharmaceuticals | 2015-05-29 |
| Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02393625) | Novartis Pharmaceuticals | 2015-05-27 |
| Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis (NCT02370706) | Novartis Pharmaceuticals | 2015-05-21 |
| Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (NCT02595970) | Novartis Pharmaceuticals | 2015-05-20 |
| 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (NCT02159053) | Novartis Pharmaceuticals | 2015-05-18 |
| Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients (NCT02442206) | Novartis Pharmaceuticals | 2015-05-18 |
| Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. (NCT02292550) | Novartis Pharmaceuticals | 2015-05-14 |
| Efficacy and Tolerability of Topical LFX453 for External Genital Warts (NCT02482428) | Novartis Pharmaceuticals | 2015-05-12 |
| Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects (NCT02404025) | Novartis Pharmaceuticals | 2015-05-12 |
| Plaque Psoriasis Efficacy and Safety With Secukinumab (NCT02409667) | Novartis Pharmaceuticals | 2015-05-07 |
| Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA (NCT02396212) | Novartis Pharmaceuticals | 2015-05-07 |
| Aliskiren Study of Safety and Efficacy in Senior Hypertensives (NCT01922141) | Novartis Pharmaceuticals | 2015-05-01 |
| A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251 (NCT02449018) | Novartis Pharmaceuticals | 2015-04-30 |
| Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations (NCT02418468) | Novartis Pharmaceuticals | 2015-04-28 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies (NCT02404441) | Novartis Pharmaceuticals | 2015-04-27 |
| Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. (NCT02140411) | Novartis Pharmaceuticals | 2015-04-25 |
| Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment (NCT02550106) | Novartis Pharmaceuticals | 2015-04-22 |